DHODH and acute myeloid leukemia: Another novel DHODH inhibitor, ASLAN003 is currently being evaluated in a phase 2a trial (NCT03451084) in AML and preclinical data on primary AML blasts grown under similar conditions as the ones used in our study revealed sensitivity in six out of fourteen AML samples [19].